Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

3SBio Acquires Rights to Novel Biologic Drug from SIMM

publication date: Oct 29, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio has acquired the China rights to a novel kidney disease treatment from the Shanghai Institute of Materia Medica. In animal models, the drug candidate slowed the progression of renal failure caused by an inherited disorder known as autosomal dominant polycystic kidney disease (ADPKD). 3SBio will ask the CFDA to approve a Phase I clinical trial in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors